Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribavirin for Mucocutaneous HCV Manifestations
NCT02261662Unknown
- Sponsor
- Tanta University
- Start
- Jun 2014
- Primary completion
- Nov 2014
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of ribavirin in lichen planus (LP), vasculitis and autoimmune diseases (2 arms), sponsored by Tanta University. Primary endpoint: Percentage of participants with improved skin manifestations of HCV infection at 6 months. Status: unknown.
02
Drugs
ribavirin
03
Conditions
lichen planus (LP)vasculitisautoimmune diseases
Beyond the preview
Go deeper on NCT02261662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02261662.